GLP-1 Medications in India: A Complete 2026 Guide
Ozempic, Wegovy, Mounjaro and the new wave of generics — what's available in India, what's DCGI-approved, what each costs after the 2026 price changes, and how to get a legitimate prescription without a months-long clinic wait.
ALTRcare Medical Team
Clinical Editorial
If you're considering GLP-1 therapy for weight loss in India, this guide covers what you actually need to know in 2026: what's available, what's approved, what it costs after a year of dramatic price changes, and how to access it safely.
What's approved and available in India (2026)
- Semaglutide — sold as Ozempic (diabetes) and Wegovy (weight management), plus 40+ generics since the March 2026 patent expiry.
- Tirzepatide — sold as Mounjaro (and Cipla's co-marketed Yurpeak); still on-patent, no generics yet.
- Oral semaglutide — Rybelsus, a daily tablet, available for Type 2 diabetes.
What each costs per month
Costs rise as you titrate up to a full therapeutic dose. The big 2026 story is the collapse in semaglutide pricing: the molecule that cost ₹15,000+ a month a year ago now starts near ₹1,290 in generic form. Tirzepatide remains the premium option because it has no generics yet.
Diabetes vs weight-management labels
Ozempic and Rybelsus are approved for Type 2 diabetes; Wegovy is the semaglutide approved for obesity. Doctors prescribe within clinical guidelines based on your profile — which is one reason supervision matters.
How to get prescribed — the two routes
The traditional route: book a clinic appointment, wait weeks for a slot, attend in person, get bloodwork done separately, then collect a prescription. For a lot of working adults, the waiting and logistics are the reason they never start.
The ALTRcare route: a 2-minute online assessment, a doctor call (often same day), bloodwork arranged for you, and — only if it's clinically appropriate — a prescription and a supervised programme with ongoing dose adjustment and side-effect support.
See if you qualify
Take the free 2-minute assessment. A doctor reviews it before anything is prescribed.
What to know before you start
- GLP-1s aren't steroids or crash diets — they're peptide medicines that work with your body's own appetite hormones.
- You'll experience reduced hunger, not starvation.
- Results are sustained while you're on treatment; stopping abruptly without a plan often leads to regain.
- Most people tolerate it well, with mild, temporary side effects in the first few weeks.
- It isn't right for everyone — baseline bloodwork and a doctor's assessment come first.
Key takeaways
- Semaglutide (incl. cheap generics), tirzepatide, and oral Rybelsus are all available in India in 2026.
- Generic semaglutide from ₹1,290/month is the biggest change; tirzepatide stays premium at ₹14,000+.
- A legitimate prescription needs an assessment and baseline bloodwork — done online in days, not months.
- GLP-1s work while you take them; a maintenance plan matters.
Have a question first?
Message our care team on WhatsApp — happy to explain options before you commit to anything.
Frequently asked questions
Which GLP-1 medications are available in India in 2026?
Semaglutide (Ozempic, Wegovy, and 40+ generics), tirzepatide (Mounjaro/Yurpeak), and oral semaglutide (Rybelsus).
How much do GLP-1 medications cost in India?
Generic semaglutide starts around ₹1,290/month, branded Ozempic/Wegovy from ₹5,660, and Mounjaro from about ₹14,000/month, rising with dose.
How do I get a GLP-1 prescription in India?
You need a doctor's assessment and baseline bloodwork. Telehealth services can do this online in a few days rather than the weeks a clinic wait often takes.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
